The most common side effects of INVEGA HAFYERA® include: injection site reactions, weight gain, headache, upper respiratory ...

Psychedelics have been growing in popularity across North America for recreational and therapeutic use, with celebrities like ...

Psychosis affects one's physical, psychological, social, and existential health. Mental health recovery often involves a ...

For patients with schizophrenia, repetitive transcranial magnetic stimulation (rTMS) was effective and safe in treating ...

Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

In a study published November 7 in the journal Cell Reports Medicine, researchers from Tufts University School of Medicine ...

Researchers have identified a potential diagnostic tool for schizophrenia by measuring brain cell activity between the ...

Shares in AbbVie slumped Monday after the company disclosed its psychiatric medicine emraclidine didn’t best placebo in two ...

With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...

Some people who took a new schizophrenia drug for a year improved with only a few side effects, but many dropped out of the ...

AbbVie's emraclidine trials for schizophrenia fail, leading to stock decline, but analysts maintain confidence in the company ...

AbbVie Inc. shares fell the most in more than four years after two mid-stage trials of its drug to treat schizophrenia failed ...